Automated method identifies and tracks harmful tau deposits involved in Alzheimer s disease
Amyloid-beta and tau are the two key abnormal protein deposits that accumulate in the brain during the development of Alzheimer s disease, and detecting their buildup at an early stage may allow clinicians to intervene before the condition has a chance to take hold. A team led by investigators at Massachusetts General Hospital (MGH) has now developed an automated method that can identify and track the development of harmful tau deposits in a patient s brain. The research, which is published in
Science Translational Medicine, could lead to earlier diagnoses of Alzheimer s disease.
Remyelinating drug shows potential to improve vision in patients with MS
A team led by a biomedical scientist at the University of California, Riverside, reports a drug an estrogen receptor ligand called indazole chloride (IndCl) has the potential to improve vision in patients with multiple sclerosis, or MS.
The study, performed on mice induced with a model of MS and the first to investigate IndCl s effect on the pathology and function of the complete afferent visual pathway, is published in
Brain Pathology. The afferent visual pathway includes the eyes, optic nerve, and all brain structures responsible for receiving, transmitting, and processing visual information.
Study: MRI is reliable for intrapelvic T staging of neuroendocrine carcinoma
Oncotarget recently published
Neuroendocrine carcinoma of uterine cervix findings shown by MRI for staging and survival analysis – Japan multicenter study which reported that to investigate neuroendocrine carcinoma of the uterine cervix cases for MRI features and staging, as well as pathological correlations and survival.
In 50 patients who underwent a radical hysterectomy and lymphadenectomy without neoadjuvant chemotherapy, intrapelvic T staging by MRI overall accuracy was 88.0% with reference to pathology staging, while patient-based sensitivity, specificity, and accuracy for metastatic pelvic lymph node detection was 38.5%, 100%, and 83.3%, respectively.
Three-year progression-free and overall survival rates for FIGO I, II, III, and IV were 64.3% and 80.9%, 50% and 64.3%, 0% and 0%, and 0% and 0%, respectively.
PKS Holidings
Highlights:
Renewal Agreement continues Philips’ use of PKS’ RippleDown product, which is now an integral part of Philips’ newly developed Laboratory Information System clinical platform replacing the current separate add-on software solution;
Philips to offer its newly developed platform which includes PKS’ RippleDown product to all of their 26 customers at no charge, thereby increasing the number of RippleDown customers.
Strong interest in the platform has been shown by potential new customers in the Netherlands and Philips are planning to roll the new platform out to other parts of Europe.
The commercial terms have been changed from fixed license fees to a per episode fee and the forecasted income for PKS over the 5-year period is in excess of €1.5m Euro (c$2.34m AUD); and